Recent Updates — ANL
Adlai Nortye Group Ltd. appointed Christopher Liu, PharmD, as Head of Investor Relations and Public Relations on September 30, 2026. Dr. Liu joins the company with nearly a decade of equity research experience in biotechnology and oncology, most recently serving as Managing Director at Lucid Capital Markets. This appointment aims to strengthen engagement with the global investment community and enhance external communications regarding the company's clinical-stage pipeline. Adlai Nortye Group Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies.
On September 8, 2026, Adlai Nortye Group Ltd. announced the dosing of its first patient in Australia for AN4035, a first-in-class antibody-drug conjugate (ADC) targeting CEACAM5 armed with a pan-RAS(ON) inhibitor payload. This event initiates the global Phase I clinical trial for patients with CEACAM5-enriched RAS-addicted solid tumors. The company also received a 'Study-May-Proceed' letter from the U.S. FDA regarding its investigational new drug application, clearing the path to expand the trial into the United States. Management aims to report full Phase Ia data in the second half of 2027 and is concurrently filing an IND with China's NMPA. Adlai Nortye Group Ltd. operates as a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies.
Adlai Nortye Ltd. reported unaudited first-half 2026 financial results and operational updates for the period ended June 30, 2026. The company raised $290 million through two private placement equity financings completed in February ($140 million) and April ($150 million). Cash and short-term investments increased to US$231.9 million from US$8.1 million at year-end 2025. Revenue rose to US$13.1 million, driven by license agreement milestones with Jiangsu Aosaikang Pharmaceutical Co., Ltd., while net loss narrowed by 70.9% to US$5.3 million. R&D expenses decreased slightly to US$14.6 million. Clinically, the company initiated enrollment in both once-daily and intermittent once-weekly arms of its global Phase I trial for pan-RAS(ON) inhibitor AN9025 and received regulatory approval in Australia for a Phase I trial of ADC AN4035. Adlai Nortye Ltd. is a clinical-stage biotechnology company focused on developing innovative cancer therapies.
Adlai Nortye Ltd. announced on August 3, 2026, that it has submitted a Clinical Trial Notification to Australia’s Therapeutic Goods Administration and received Human Research Ethics Committee approval to commence its Phase I clinical trial for AN4035. This first-in-class antibody drug conjugate targets CEACAM5-enriched RAS-addicted solid tumors using the company's proprietary RASiCA platform. Patient dosing is expected to begin in the second half of 2026, with investigational new drug applications also pending with the U.S. FDA and China NMPA. Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies.